AstraZeneca across Pulmonology: the full competitive set, and the 1 AXLRx report mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.
Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier.
We use analytics cookies to see how visitors use AXLRx. They're only set if you accept — decline and none are placed. See our Privacy Policy.